Utilising ERα ChIP-Seq performed in human patients with HR+ disease,30 binding sites for ERα were identified in the genomic region of MIR196A. This tumour cohort contains three groups of tumours, (1) tumours from women who respond to HR therapy, (2) those who do not and (3) metastases from resistant tumours. Here, ESR1 is linked to neoplasm.